2-Pyrrolidone

2-Pyrrolidone

SCHEMBL2030191

C=C(C)C(=O)OC(C)N=C=O.O=C1CCCN1

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
OR51E2 Q9H255 1/20 0.39
FKBP5 Q13451 1/20 0.34
CRBN Q96SW2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Caprolactam SCHEMBL2036757 0.95 FKBP5 (0.39) OR51E2FKBP5CRBN
2-Pyrrolidone SCHEMBL12468588 0.81 OR51E2 (0.46) OR51E2FKBP5CRBN
SCHEMBL35491 0.80 TSHR (0.39)
2-Pyrrolidone SCHEMBL28304484 0.80 OR51E2 (0.44) OR51E2FKBP5CRBN
2-Pyrrolidone SCHEMBL28096599 0.77 OR51E2 (0.42) OR51E2FKBP5CRBN
Caprolactam SCHEMBL6747085 0.76 FKBP5 (0.46) OR51E2FKBP5CRBN
Methacrylic Acid SCHEMBL27993923 0.76 TSHR (0.36)
SCHEMBL9472415 0.76 TSHR (0.36)
2-Pyrrolidone SCHEMBL2030192 0.74 OR51E2 (0.39) OR51E2FKBP5CRBN
2-Pyrrolidone SCHEMBL27469716 0.74 OR51E2 (0.39) OR51E2FKBP5CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3004050-B1 CYANOSTILBENES ROLIC TECH AG (CH) 2020-09-02 EP disclosed
CN-111533668-A Cyanostilbenes 罗利克技术有限公司 2020-08-14 CN disclosed
US-10329486-B2 Cyanostilbenes ROLIC AG (CH) 2019-06-25 US disclosed
EP-3004050-A1 CYANOSTILBENES Rolic AG (CH) 2016-04-13 EP disclosed
US-20160083655-A1 CYANOSTILBENES ROLIC AG (CH) 2016-03-24 US disclosed
WO-2014191292-A1 CYANOSTILBENES ROLIC AG (CH) 2014-12-04 WO disclosed
US-7959990-B2 Adjustment of liquid crystals; oligomers, dendrimers, or polymer in solution is applied to support; crosslinking by radiation or polarized light ROLIC AG (CH) 2011-06-14 US disclosed
EP-1928979-B1 FUNCTIONALIZED PHOTOREACTIVE COMPOUNDS ROLIC AG (CH) 2009-03-04 EP disclosed
US-20080274304-A1 Functionalized Photoreactive Compounds ROLIC AG (CH) 2008-11-06 US disclosed
EP-1928979-A1 FUNCTIONALIZED PHOTOREACTIVE COMPOUNDS Rolic AG (CH) 2008-06-11 EP disclosed
WO-2007033506-A1 FUNCTIONALIZED PHOTOREACTIVE COMPOUNDS ROLIC AG (CH) 2007-03-29 WO disclosed
EP-1764405-A1 Functionalized photoreactive compounds Rolic AG (CH) 2007-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080274304-A1 Functionalized Photoreactive Compounds PCNA, PIN1, MAP1LC3C OR51E2 2880/4885FKBP5 263/4885CRBN 4237/4885
US-20160083655-A1 CYANOSTILBENES LATS1, LATS2, CRY1 OR51E2 1009/4885FKBP5 812/4885CRBN 48/4885
US-10329486-B2 Cyanostilbenes LATS1, LATS2, CRY1 OR51E2 1009/4885FKBP5 812/4885CRBN 48/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.